Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Insulin for Liver Function and Regeneration
NCT06126419Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of human insulin in hepatic dysfunction (3 arms), sponsored by McGill University Health Centre. Primary endpoints: Liver function improvement measured with 99mTc-Mebrofenin Hepatobiliary Scintigraphy at 7 days and Liver regeneration improvement measured by CT volumetry at 7 days. Started Nov 2023; status: recruiting.
02
Drugs
human insulin
03
Conditions
hepatic dysfunction
Beyond the preview
Go deeper on NCT06126419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126419.